Key Takeaways
- Strong headline growth, API price risk: Revenue grew 19% YoY to ₹352 crores and EBITDA rose 28%, but a sharp drop in key API prices is compressing per-unit revenue and clouds the full-year outlook.
- Jammu ramp-up is the central story: The new Jammu facility commercialized in January 2025 and is targeted to reach ₹400 crores in FY26 revenue, though that target assumes API prices stabilize.
- Branded generics surged on exports: The segment grew 59% YoY to ₹101.2 crores, driven by ROW export markets, while CDMO grew a steadier 8% to ₹249.5 crores.
- Margins improved but visibility is low: EBITDA margin expanded to 16.1% from 15.1% YoY, yet management deferred margin guidance, citing too many moving parts in the Jammu ramp-up.
- What to watch next quarter: Whether API prices stabilize, the pace of Jammu’s quarterly revenue march toward ₹100 crores, and any clarity on branded generics growth sustainability.
Jammu Facility Ramp-Up
- Scale-up on track: The greenfield Kathua facility commercialized in January 2025 and generated ~₹60 crores in Q1, with strong CDMO client interest and good branded generics demand supporting the ramp-up.
- Revenue target is conditional: Management anticipates ₹400 crores in FY26 Jammu revenue, but that estimate assumes constant API pricing; API prices are currently showing declining trends of up to 20%.
- Top priority is velocity: The company’s stated top priority is reaching a ₹100 crore quarterly revenue run-rate at Jammu as fast as possible, with PAT breakeven hoped for by year-end.
- Capacity unlocked, one bottleneck remains: Jammu removed the cephalosporin capacity constraint, and tablet and capsule capacity is available, but the oral liquid section remains constrained.
- Margin visibility deferred: Management says the ramp-up is complex with many moving parts and a clearer picture on margins will only emerge in coming quarters, though long-run margin uplift is anticipated once Jammu stabilizes.
Lohariwala: "As a company, it is our top priority that how fast we reach at a ₹100 crore level from Jammu."
API Pricing & Revenue Mechanics
- Potassium clavulanate crash: The API price fell from ₹18,500 to ₹13,000, creating what management called “very big turmoil” for the market.
- Pass-through model amplifies the hit: The company’s pricing has two components, roughly 50-50: a fixed constant and a percentage tied to profitability. When API prices drop, absolute per-unit revenue drops even if the margin percentage holds.
- Guidance hinges on stabilization: Management stated that if API prices stabilize, it should be able to retain its revenue guidance; the conditional language leaves the guidance exposed to further declines.
- Industry capacity explains the pressure: Post-COVID capacity expansion in Pen G, 7ACA and core KSM is a big reason for price drops, and with the market growing at 10-12%, capacity needs to double every 6-7 years to avoid scarcity.
Bhasin: "We should be able to reach to a final conclusion or a more concrete conclusion where our this year of Jammu revenue will lie and subject to the stabilization of API prices."
Business Reorganization
- Two verticals, one framework: The company reorganized into CDMO and branded generics, with Sharon now fully integrated within the Innova framework.
- CDMO vertical: Comprises the legacy CDMO operation, the Sharon business, and part of the international branded generic portfolio operating under a CDMO framework.
- Branded generics vertical: Includes the domestic branded generic business and the portion of the international branded generic portfolio run on a front-end branded model.
- Segmental history withheld: When asked for the previous quarter’s breakup under the new structure, management declined to provide it on the call, saying they would work it out and reach out offline.
Lohariwala: "With Sharon now fully integrated within the Innova framework and keeping in mind our business modality, we believe that this new structure better reflects the way we operate today and how we create value across our portfolio."
Baddi-to-Jammu Product Transfer
- Transfer underway, Baddi sales dip: Products are being shifted from Baddi to Jammu, causing a temporary drop in Baddi sales; the net QoQ increase from Jammu was ₹60 crores.
- Strategic split by market: The plan is for Baddi’s cephalosporin line to move 100% toward export-oriented business, while Jammu, which benefits from domestic GST incentives, will cater to domestic business.
- Transfer quantum undisclosed: Management declined to quantify how much of the ₹60 crores Jammu revenue came from Baddi transfer, calling it “a bit difficult to comment on.”
- Normalization timeline vague: Baddi is expected to return to its usual revenue run-rate after product transfers normalize, but no specific timeline was given.
Lohariwala: "But as we progress, our planning is that the Baddi Cephalosporin will be 100% move towards the export-oriented business. And the Jammu facility as we have the domestic GST benefit as well, so that will cater to the domestic business."
Branded Generics & Export Growth
- Exports drove the surge: Strong growth in the export branded generic business, particularly from ROW markets, powered the 59% YoY branded generics jump.
- Sustainability unquantified: When asked if the 59% growth rate would sustain on a full-year FY26 basis, management said it is “still working on that” and could not provide an exact percentage.
- Therapeutic and geographic detail withheld: Management said growth is spread across 10-15 therapeutic categories and from ROW markets, but declined to provide a specific breakdown by segment or geography.
Cost Structure & Margin Outlook
- Semi-variable cost base: Major costs including employee and other operating expenses are semi-variable; with Jammu at ~₹60 crores and Baddi at steady-state, further revenue increases will not result in proportionate cost increases.
- GST incentive mechanics: The company has a fixed incentive of ~₹75 crores; a lower GST rate means higher sales are needed to achieve the same incentive, and vice versa. Management dismissed GST rate-change scenarios as “very hypothetical.”
- Long-run margin optimism, near-term opacity: Management anticipates upward margin movement once Jammu stabilizes, but declined to provide even a ballpark EBITDA margin guidance for now, citing too many moving parts.
Bhasin: "In the long run, when we are anticipating that Jammu will stabilize, we are surely anticipating a certain upward movement on our margins, but we should be able to provide a more clear picture in our coming quarters."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Jammu revenue target | ₹400 crores in FY26 | FY26, subject to API price stabilization |
| Jammu quarterly run-rate | Reach ₹100 crore quarterly revenue level | No date; top priority |
| Jammu PAT breakeven | PAT positive | Hoped for by end of FY26 |
| Baddi revenue normalization | Return to usual run-rate | After product transfers normalize (no date) |
| Full-year revenue guidance | Retain existing guidance | Conditional on API price stabilization |
Key Metrics
| Metric | Q1 FY26 |
|---|---|
| Revenue | ₹351.5 cr, +19% YoY |
| CDMO revenue | ₹249.5 cr, +8% YoY; 71% of total revenue |
| Branded generics revenue | ₹101.2 cr, +59% YoY |
| EBITDA | ₹56.6 cr, +28% YoY |
| EBITDA margin | 16.1%, up from 15.1% in Q1 FY25 |
| PAT | ₹31 cr, +5% YoY |
| PAT margin | 8.8% |
| Jammu plant revenue | ₹60 cr in Q1; annual target ₹400 cr at constant API pricing |
| Jammu plant operational breakeven | ₹60–65 cr quarterly revenue |
| Jammu plant PAT breakeven | ₹100 cr quarterly revenue |
| Jammu plant utilization | less than 5% |
| ICL standalone business growth | ~26.5% YoY |
| API price decline | as high as 20% in certain cases |
| GST incentive available | ~₹75 cr fixed; requires ~₹600–620 cr sales at current 12% rate |